H.C. Wainwright analyst Yi Chen initiated coverage of AxoGen (AXGN) with a Buy rating and $25 price target Axogen is a ommercial-stage medical device company focused on development of products for peripheral nerve regeneration and repair, the analyst tells investors in a research note. The firm says near-term FDA approval could expand adoption of Avance. It expects AxoGen to see solid sales growth in the coming years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- Optimistic Buy Rating for AxoGen Amid Regulatory Delays and Market Potential
- Keurig Dr Pepper buys JDE Peet’s, Thoma Bravo to acquire Verint: Morning Buzz
- FDA Extends Review for AxoGen’s Avance Nerve Graft
- AxoGen: FDA extends PDUFA date for BLA for Avance Nerve Graft to December 5
- AxoGen price target lowered to $20 from $21 at Raymond James